Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures

Summary

GBI Research, the leading business intelligence provider, has released its latest research Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures. The report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in China with key data, information and analysis of pricing and reimbursement steps. The report closely scrutinizes major changes in the pharmaceuticals-related pricing and reimbursement scene in China, due to the implementation of the 2009 Healthcare Reform.

Pricing and reimbursement is of paramount importance in China because of the rapidly rising expenditure on drugs. These issues become more acute because of the large population in China, and its associated effects on expenditure on drugs. Although the rapidly growing population and shift towards urbanization offer a large market for drug manufacturers, the market is tempered by the pricing and reimbursement system in China. Challenges faced by companies entering the Chinese pharmaceutical market include government price controls, extensive retail mark-ups, and wide regional variations in insurance.

Pharmaceutical price and pharmaceutical quantity are major factors contributing to healthcare expenditure. The control of retail prices alone is not effective in containing healthcare expenditures; it is also essential to prescribe efficient pharmaceutical utilization. Efficient pharmaceutical utilization is achieved by the use of appropriate reimbursement mechanisms, and a prospective payment system. This cost-driving reimbursement mechanism is incompatible with the goal of containing health-care costs. The reform of the reimbursement mechanism therefore plays a vital role in the changing incentives to the providers. The new reimbursement mechanism provides incentives to healthcare professionals, encouraging efficiency and cost savings when using all health resources, including drugs. The new reimbursement mechanism is an effective countermeasure for the Chinese healthcare system, which is plagued by over-prescription, abuse of quality technology services and cost shifting. A large part of the pharmaceutical market growth is propelled by the expansion of the public sector health insurance coverage, which also includes a greater reimbursement of drugs.

Scope

- Detailed study of the healthcare scenario in the China
- Analysis of the pricing and reimbursement mechanisms in China
- Key changes that follow on from the implementation of new Healthcare Reform 2009 within the pricing and reimbursement system
- Details about government bodies which regulate different processes of pricing and reimbursement in China
- Insight into various reimbursement programs in China

Reasons to buy

- Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in China
- Optimize your investment through identification and understanding of the changes in the pharmaceutical regulatory mechanisms in China
- Gain knowledge regarding the regulatory bodies who undertake different processes of price registration
- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene in China
- Negotiate better with the government agencies to maximize reimbursement on the drugs by understanding the mechanism